Global Peptide-Drug Conjugates Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Peptide-Drug Conjugates
    1.2 Classification of Peptide-Drug Conjugates by Type
        1.2.1 Overview: Global Peptide-Drug Conjugates Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Peptide-Drug Conjugates Revenue Market Share by Type in 2021
        1.2.3 Cell-penetrating Peptides (CPPs)
        1.2.4 Cell-targeting Peptides (CTPs)
    1.3 Global Peptide-Drug Conjugates Market by Application
        1.3.1 Overview: Global Peptide-Drug Conjugates Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Carcinoma
        1.3.3 Sarcoma
        1.3.4 Melanoma
        1.3.5 Lymphoma
        1.3.6 Leukemia
    1.4 Global Peptide-Drug Conjugates Market Size & Forecast
    1.5 Global Peptide-Drug Conjugates Market Size and Forecast by Region
        1.5.1 Global Peptide-Drug Conjugates Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Peptide-Drug Conjugates Market Size by Region, (2017-2022)
        1.5.3 North America Peptide-Drug Conjugates Market Size and Prospect (2017-2028)
        1.5.4 Europe Peptide-Drug Conjugates Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Peptide-Drug Conjugates Market Size and Prospect (2017-2028)
        1.5.6 South America Peptide-Drug Conjugates Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Peptide-Drug Conjugates Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Peptide-Drug Conjugates Market Drivers
        1.6.2 Peptide-Drug Conjugates Market Restraints
        1.6.3 Peptide-Drug Conjugates Trends Analysis
2 Company Profiles
    2.1 AstraZeneca
        2.1.1 AstraZeneca Details
        2.1.2 AstraZeneca Major Business
        2.1.3 AstraZeneca Peptide-Drug Conjugates Product and Solutions
        2.1.4 AstraZeneca Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 AstraZeneca Recent Developments and Future Plans
    2.2 Bicycle Therapeutics
        2.2.1 Bicycle Therapeutics Details
        2.2.2 Bicycle Therapeutics Major Business
        2.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Product and Solutions
        2.2.4 Bicycle Therapeutics Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Bicycle Therapeutics Recent Developments and Future Plans
    2.3 Cybrexa Therapeutics
        2.3.1 Cybrexa Therapeutics Details
        2.3.2 Cybrexa Therapeutics Major Business
        2.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Product and Solutions
        2.3.4 Cybrexa Therapeutics Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Cybrexa Therapeutics Recent Developments and Future Plans
    2.4 Esperance Pharmaceuticals
        2.4.1 Esperance Pharmaceuticals Details
        2.4.2 Esperance Pharmaceuticals Major Business
        2.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Product and Solutions
        2.4.4 Esperance Pharmaceuticals Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Esperance Pharmaceuticals Recent Developments and Future Plans
    2.5 Oncopeptides
        2.5.1 Oncopeptides Details
        2.5.2 Oncopeptides Major Business
        2.5.3 Oncopeptides Peptide-Drug Conjugates Product and Solutions
        2.5.4 Oncopeptides Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Oncopeptides Recent Developments and Future Plans
    2.6 Pepgen Corporation
        2.6.1 Pepgen Corporation Details
        2.6.2 Pepgen Corporation Major Business
        2.6.3 Pepgen Corporation Peptide-Drug Conjugates Product and Solutions
        2.6.4 Pepgen Corporation Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Pepgen Corporation Recent Developments and Future Plans
    2.7 Soricimed Biopharma
        2.7.1 Soricimed Biopharma Details
        2.7.2 Soricimed Biopharma Major Business
        2.7.3 Soricimed Biopharma Peptide-Drug Conjugates Product and Solutions
        2.7.4 Soricimed Biopharma Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Soricimed Biopharma Recent Developments and Future Plans
    2.8 Theratechnologies
        2.8.1 Theratechnologies Details
        2.8.2 Theratechnologies Major Business
        2.8.3 Theratechnologies Peptide-Drug Conjugates Product and Solutions
        2.8.4 Theratechnologies Peptide-Drug Conjugates Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Theratechnologies Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Peptide-Drug Conjugates Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Peptide-Drug Conjugates Players Market Share in 2021
        3.2.2 Top 10 Peptide-Drug Conjugates Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Peptide-Drug Conjugates Players Head Office, Products and Services Provided
    3.4 Peptide-Drug Conjugates Mergers & Acquisitions
    3.5 Peptide-Drug Conjugates New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Peptide-Drug Conjugates Revenue and Market Share by Type (2017-2022)
    4.2 Global Peptide-Drug Conjugates Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
    5.1 Global Peptide-Drug Conjugates Revenue Market Share by Application (2017-2022)
    5.2 Global Peptide-Drug Conjugates Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
    6.1 North America Peptide-Drug Conjugates Revenue by Type (2017-2028)
    6.2 North America Peptide-Drug Conjugates Revenue by Application (2017-2028)
    6.3 North America Peptide-Drug Conjugates Market Size by Country
        6.3.1 North America Peptide-Drug Conjugates Revenue by Country (2017-2028)
        6.3.2 United States Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        6.3.3 Canada Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        6.3.4 Mexico Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
    7.1 Europe Peptide-Drug Conjugates Revenue by Type (2017-2028)
    7.2 Europe Peptide-Drug Conjugates Revenue by Application (2017-2028)
    7.3 Europe Peptide-Drug Conjugates Market Size by Country
        7.3.1 Europe Peptide-Drug Conjugates Revenue by Country (2017-2028)
        7.3.2 Germany Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        7.3.3 France Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        7.3.5 Russia Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        7.3.6 Italy Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Peptide-Drug Conjugates Revenue by Type (2017-2028)
    8.2 Asia-Pacific Peptide-Drug Conjugates Revenue by Application (2017-2028)
    8.3 Asia-Pacific Peptide-Drug Conjugates Market Size by Region
        8.3.1 Asia-Pacific Peptide-Drug Conjugates Revenue by Region (2017-2028)
        8.3.2 China Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        8.3.3 Japan Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        8.3.4 South Korea Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        8.3.5 India Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        8.3.7 Australia Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
    9.1 South America Peptide-Drug Conjugates Revenue by Type (2017-2028)
    9.2 South America Peptide-Drug Conjugates Revenue by Application (2017-2028)
    9.3 South America Peptide-Drug Conjugates Market Size by Country
        9.3.1 South America Peptide-Drug Conjugates Revenue by Country (2017-2028)
        9.3.2 Brazil Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        9.3.3 Argentina Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Peptide-Drug Conjugates Revenue by Type (2017-2028)
    10.2 Middle East & Africa Peptide-Drug Conjugates Revenue by Application (2017-2028)
    10.3 Middle East & Africa Peptide-Drug Conjugates Market Size by Country
        10.3.1 Middle East & Africa Peptide-Drug Conjugates Revenue by Country (2017-2028)
        10.3.2 Turkey Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
        10.3.4 UAE Peptide-Drug Conjugates Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer